Abe, Kodai
Kitago, Minoru
Iwasaki, Eisuke
Yagi, Hiroshi
Abe, Yuta
Hasegawa, Yasushi
Hori, Shutaro
Tanaka, Masayuki
Nakano, Yutaka
Kitagawa, Yuko
Article History
Received: 13 October 2022
Accepted: 5 November 2022
First Online: 18 November 2022
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Keio University School of Medicine (protocol code 20120443). The study was reviewed and approved for publication by our Institutional Review board. All study participants provided informed consent.
: Not applicable
: YK received grants from Chugai Pharmaceutical Co., LTD.; Taiho Pharmaceutical Co., Ltd; Yakult Honsha Co. Ltd.; Asahi Kasei Pharma Corporation EA Pharma Co., Ltd.; Astellas Pharma Inc.; Toyama Chemical Co., Ltd.; Medicon Inc.; Kaken Pharmaceutical Co. Ltd.; Eisai Co., Ltd.; Otsuka Pharmaceutical Factory Inc.; Teijin Pharma Limited; Nihon Pharmaceutical Co., Ltd.; Nippon Covidien Inc.; Shionogi & Co., Ltd.; Olympus Corporation AstraZeneca K.K.; Ethicon, Inc.; MSD K.K.; Otsuka Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Tsumura & CO.; Kyouwa Hakkou Kirin Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; Smith&Nephew KK; and Bristol-Myers Squibb K.K.